EDN1 and Hypertension: On the other hand, rhEPO has been observed to foster the production of two molecules, endothelin 1 (ET-1) and plasminogen activator inhibitor 1 (PAI1), both leading to an increase in vascular resistance resulting in hypertension seen in patients with chronic kidney disease (CKD) [21].